title: Decreased cyclin B1 expression contributes to G2 delay in human brain tumor cells after treatment with camptothecin.
abstract: DNA damage produces delayed mitosis (G2/M delay) in proliferating cells, and shortening the delay sensitizes human malignant glioma and medulloblastoma cells to cytotoxic chemotherapy. Although activation of the cyclin-dependent kinase CDC2 mediates G2/M transition in all tumor cells studied to date, regulation of CDC2 varies between tumor types. Persistent hyperphosphorylation of kinase and reduced cyclin expression have been implicated as mediators of treatment-induced G2 delay in different tumor models. To evaluate regulation of G2/M transition in human brain tumors, we studied the expression and/or activity of CDC2 kinase and cyclins A and B1 in U-251 MG and DAOY medulloblastoma cells after their treatment with camptothecin (CPT). Synchronized cells were treated during S phase, then harvested at predetermined intervals for evaluation of cell cycle kinetics, kinase activity mRNA, and protein expression. CPT produced G2 delay associated with decreased CDC2 kinase activity and cyclin B1 expression. Kinase activity was associated with CDC2 bound to cyclin B1, not cyclin A, in both cell lines. Cyclin A mRNA and protein expression were reduced after CPT treatment; however, decreased protein expression was short lived and moderate in the glioma and primitive neuroectodermal tumor/medulloblastoma cells, respectively. We conclude that G2 delay is a common response of brain tumor cells to chemotherapy with topoisomerase I inhibitors and that a mechanism of this delay may be reduced expression of cyclin B1.
authors: Division of Neurology, Children's Hospital of Philadelphia, PA 19104-9786, USA.
authors: A J
authors: AJ
authors: Janss
authors: A
authors: A
authors: Maity
authors: C B
authors: CB
authors: Tang
authors: R J
authors: RJ
authors: Muschel
authors: W G
authors: WG
authors: McKenna
authors: L
authors: L
authors: Sutton
authors: P C
authors: PC
authors: Phillips
mesh_terms: D000972:Antineoplastic Agents, Phytogenic / Q000494:pharmacology*; D001932:Brain Neoplasms / Q000235:genetics* / Q000473:pathology; D016203:CDC2 Protein Kinase / Q000378:metabolism; D002166:Camptothecin / Q000494:pharmacology*; D019925:Cyclin A / Q000096:biosynthesis / Q000235:genetics; D019926:Cyclin B / Q000096:biosynthesis* / Q000235:genetics; D056744:Cyclin B1; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D016195:G2 Phase / Q000187:drug effects*; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects*; D005910:Glioma / Q000235:genetics* / Q000473:pathology; D006801:Humans; D008527:Medulloblastoma / Q000235:genetics* / Q000473:pathology; D009363:Neoplasm Proteins / Q000037:antagonists & inhibitors / Q000096:biosynthesis* / Q000235:genetics; D012333:RNA, Messenger / Q000096:biosynthesis / Q000235:genetics; D059004:Topoisomerase I Inhibitors; D014407:Tumor Cells, Cultured / Q000187:drug effects
chemical_list: D000972:Antineoplastic Agents, Phytogenic; C534699:CCNB1 protein, human; D019925:Cyclin A; D019926:Cyclin B; D056744:Cyclin B1; D004791:Enzyme Inhibitors; D009363:Neoplasm Proteins; D012333:RNA, Messenger; D059004:Topoisomerase I Inhibitors; D016203:CDC2 Protein Kinase; D002166:Camptothecin